Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pearson profits jump 10%, unveils £350m buyback

(Sharecast News) - Education publisher Pearson on Friday said annual profit rose 10% driven by growth in its English language learning operations and unveiled a £350m share buyback as it reiterated guidance for 2025.

Full-year adjusted operating profit came in at £600m, at the upper end of guidance, while the final dividend was lifted to 24p a share.

Chief executive Omar Abbosh said an accelerated rollout of artificial intelligence across its products remained a priority.

"We also continue to focus on expanding our presence in the highly attractive Enterprise skills market at a time where Pearson can play an important role in helping bridge the critical skills gap that impacts the economy, workforce and individuals," he said.

AJ Bell investment director said Pearson had "achieved a leading role in online learning".

"Profit for the year came in at the top end of expectations with strong growth in English language learning. Alongside the numbers, the company has announced an expansion of its existing tie-up with Amazon's AWS cloud computing operation. AWS will support Pearson to further integrate AI into its offering."

"Pearson has already brought in innovations like an AI tutor which helps children with their homework, and an assessment tool for teachers to help them with lesson plans. While there will be excitement about the potential, investors will increasingly want to see evidence of how AI is delivering returns for the business too."

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.